Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess
4 affiliations
- 1Department of General Surgery, Changshu No. 2 People’s Hospital, Affiliated Hospital of Nantong University
- 2Department of Laboratory Medicine, Nanjing Zhongda Hospital, School of Medicine, Southeast University
- 3Pediatric Intensive Care Unit, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School
- 4Department of General Surgery, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School
Abstract
Background: Endocrine therapy is central to the treatment of hormone receptor-positive breast cancer, yet hepatobiliary adverse-event reporting across endocrine agents remains incompletely characterized. We evaluated hepatobiliary reporting patterns and disproportionality signals using FAERS, with VigiAccess as a supplementary data source.
Methods: FAERS data from Q1–2004 to Q1–2026 were analyzed for seven endocrine therapies: tamoxifen, toremifene, anastrozole, letrozole, exemestane, fulvestrant, and elacestrant. Hepatobiliary adverse events were identified using prespecified MedDRA Preferred Terms (PTs). Drug-level disproportionality was assessed using reporting odds ratios (RORs) and information components (ICs) within a FAERS reference population restricted by breast cancer indication and primary-suspect drug role. PT- and HLT-level reporting patterns, class-level differences, sensitivity analyses, and time-to-onset (TTO) characteristics were also explored. VigiAccess was used for a non-equivalent exploratory disproportionality comparison based on aggregated adverse-event term counts.
Results: The FAERS hepatobiliary cohort comprised 2,630 unique case reports meeting the prespecified target-drug, breast cancer indication, primary-suspect, and hepatobiliary adverse-event criteria. Toremifene showed the largest disproportionality estimate [ROR = 5.91, 95% CI: 4.55–7.68; IC = 2.45, IC025 = 1.96], with positive signals also observed for letrozole, exemestane, and fulvestrant. Tamoxifen, anastrozole, and elacestrant did not meet the predefined positive-signal criteria. Signals for toremifene, letrozole, and exemestane were robust across sensitivity analyses, whereas the weak fulvestrant signal was more sensitive to alternative endpoint definitions, drug-role classifications, and clinical-context exclusions. The VigiAccess analysis showed concordance for the prominent toremifene signal but discordant findings for tamoxifen, letrozole, and exemestane. PT- and HLT-level analyses showed exploratory differences in reported hepatobiliary event distributions across drugs and therapy classes. TTO analyses suggested an earlier concentration of reported onset times at the class level, although within-class heterogeneity and incomplete timing data limited interpretation.
Conclusions: This pharmacovigilance study identified heterogeneous hepatobiliary adverse-event reporting patterns and disproportionality signals across endocrine therapies used in breast cancer. Toremifene, letrozole, and exemestane showed consistent signals across multiple sensitivity analyses, whereas other agents demonstrated more context-dependent patterns. These findings should be regarded as hypothesis-generating pharmacovigilance evidence rather than estimates of clinical incidence, comparative safety, or causal hepatotoxicity and require confirmation in clinical and pharmacoepidemiologic studies.
Related
- Ocular adverse event profiles associated with endocrine therapies for breast cancer: a global pharmacovigilance study using FAERS and VigiAccess
- Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).
- Real-world pharmacovigilance analysis and cross-database consistency assessment of resmetirom-related adverse events using FAERS and VigiAccess
- Dementia-related risk associated with endocrine and targeted therapy strategies in breast cancer: a real-world pharmacovigilance analysis
- Adverse Drug Reaction Reporting Among Herbal Practitioners: A Mixed-Methods Study of Reporting Practices, Associated Factors, and Pharmacovigilance System Barriers in the Greater Accra Region, Ghana
BibTeX
@article{mao2026hepatobiliary,
title = {{Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess}},
author = {Weiguo Mao and Yonghui Liu and Ben Liu and Bin Zhu},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1940744},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1940744/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess
AU - Weiguo Mao
AU - Yonghui Liu
AU - Ben Liu
AU - Bin Zhu
PY - 2026
DA - 2026/10/23
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1940744
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1940744/full
AB - Background: Endocrine therapy is central to the treatment of hormone receptor-positive breast cancer, yet hepatobiliary adverse-event reporting across endocrine agents remains incompletely characterized. We evaluated hepatobiliary reporting patterns and disproportionality signals using FAERS, with VigiAccess as a supplementary data source. Methods: FAERS data from Q1–2004 to Q1–2026 were analyzed for seven endocrine therapies: tamoxifen, toremifene, anastrozole, letrozole, exemestane, fulvestrant, and elacestrant. Hepatobiliary adverse events were identified using prespecified MedDRA Preferred Terms (PTs). Drug-level disproportionality was assessed using reporting odds ratios (RORs) and information components (ICs) within a FAERS reference population restricted by breast cancer indication and primary-suspect drug role. PT- and HLT-level reporting patterns, class-level differences, sensitivity analyses, and time-to-onset (TTO) characteristics were also explored. VigiAccess was used for a non-equivalent exploratory disproportionality comparison based on aggregated adverse-event term counts. Results: The FAERS hepatobiliary cohort comprised 2,630 unique case reports meeting the prespecified target-drug, breast cancer indication, primary-suspect, and hepatobiliary adverse-event criteria. Toremifene showed the largest disproportionality estimate [ROR = 5.91, 95% CI: 4.55–7.68; IC = 2.45, IC025 = 1.96], with positive signals also observed for letrozole, exemestane, and fulvestrant. Tamoxifen, anastrozole, and elacestrant did not meet the predefined positive-signal criteria. Signals for toremifene, letrozole, and exemestane were robust across sensitivity analyses, whereas the weak fulvestrant signal was more sensitive to alternative endpoint definitions, drug-role classifications, and clinical-context exclusions. The VigiAccess analysis showed concordance for the prominent toremifene signal but discordant findings for tamoxifen, letrozole, and exemestane. PT- and HLT-level analyses showed exploratory differences in reported hepatobiliary event distributions across drugs and therapy classes. TTO analyses suggested an earlier concentration of reported onset times at the class level, although within-class heterogeneity and incomplete timing data limited interpretation. Conclusions: This pharmacovigilance study identified heterogeneous hepatobiliary adverse-event reporting patterns and disproportionality signals across endocrine therapies used in breast cancer. Toremifene, letrozole, and exemestane showed consistent signals across multiple sensitivity analyses, whereas other agents demonstrated more context-dependent patterns. These findings should be regarded as hypothesis-generating pharmacovigilance evidence rather than estimates of clinical incidence, comparative safety, or causal hepatotoxicity and require confirmation in clinical and pharmacoepidemiologic studies.
SN - 1664-2392
ER -